World Journal of Gastroenterology - Baishideng Publishing Group

BPG is committed to discovery and dissemination of knowledge

Cited by in CrossRef

For:	Albader F, Golovics PA, Gonczi L, Bessissow T, Afif W, Lakatos PL. Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring. World J Gastroenterol 2021; 27(37): 6231-6247 [PMID: 34712029 DOI: 10.3748/wjg.v27.i37.6231]
URL:	https://www.wjgnet.com/1007-9327/full/v27/i37/6231.htm

(312) (228) (0) (0) (0) (7) (2) (8968) (23)

Number	Citing Articles
1	Steven Levitte. Point-of-Care Assays for Infliximab Therapeutic Drug Monitoring in Patients with IBD: Is Quicker Better?. Digestive Diseases and Sciences 2024; 69(1) doi: 10.1007/s10620-023-08140-8
2	Karine Rodriguez-Fernandez, Javier Zarzoso-Foj, Marina Saez-Bello, Almudena Mateu-Puchades, Antonio Martorell-Calatayud, Matilde Merino-Sanjuan, Elena Gras-Colomer, Monica Climente-Marti, Victor Mangas-Sanjuan. Personalized Secukinumab Treatment in Patients with Plaque Psoriasis Using Model-Informed Precision Dosing. Pharmaceutics 2024; 16(12) doi: 10.3390/pharmaceutics16121576
3	Akshita Bhalla, Anushka Shahi , Madhurima Maity, FNU Safa, Vindlacheruvu Srividya, Ruchira Clementina, Goutham R Anugu, Salma Younas. Inflammatory Bowel Disease in Children: Current Diagnosis and Treatment Strategies. Cureus 2025; doi: 10.7759/cureus.78462
4	Karine Rodríguez-Fernández, Javier Zarzoso-Foj, Marina Saez-Bello, Almudena Mateu-Puchades, Antonio Martorell-Calatayud, Matilde Merino-Sanjuan, Elena Gras-Colomer, Monica Climente-Martí, Victor Mangas-Sanjuan. Model-Informed Precision Dosing for Personalized Ustekinumab Treatment in Plaque Psoriasis. Pharmaceutics 2024; 16(10) doi: 10.3390/pharmaceutics16101295
5	Thea H. Wiken, Marte L. Høivik, Karoline Anisdahl, Lydia Buer, Bjørn A. Moum, David J. Warren, Nils Bolstad, Milada Hagen, Asle W. Medhus. Real‐World Comparison of Vedolizumab and Ustekinumab in TNF Inhibitor–Experienced Ulcerative Colitis Patients Followed by Therapeutic Drug Monitoring. JCC Plus 2026; 1(2) doi: 10.1002/jcc5.70011
6	Li-Xuan Sang, Chang-Qing Zheng, Jing-Wen Zhao, Meng-Yao Wang. Therapeutic drug monitoring in inflammatory bowel disease treatments. World Journal of Gastroenterology 2022; 28(15): 1604-1607 doi: 10.3748/wjg.v28.i15.1604 Abstract(964) \| Core Tip(926) \| Full Article(HTML)(2840) \| Full Article (PDF)-624K(420) \| Full Article (Word)-112K(79) \| Audio-298K(12) \| Peer-Review Report-230K(234) \| Answering Reviewers-268K(184) \| Times Cited (2) \| Total Visits (3339) \| Open
7	A.N. Tarashchuk, M.E. Zharova, I.O. Ivanikov. Maintenance immunosuppressive therapy for Crohn’s disease: patient adherence and its impact on treatment efficacy. Case report. Russian Journal of Evidence-Based Gastroenterology 2024; 13(2) doi: 10.17116/dokgastro20241302190
8	Alina Ecaterina Jucan, Otilia Gavrilescu, Mihaela Dranga, Iolanda Valentina Popa, Ioana-Ruxandra Mihai, Vasile-Claudiu Mihai, Gabriela Stefanescu, Vasile Liviu Drug, Cristina Cijevschi Prelipcean, Radu-Alexandru Vulpoi, Oana-Bogdana Barboi, Irina Ciortescu, Catalina Mihai. Evaluation of Disease Activity in Inflammatory Bowel Disease: Diagnostic Tools in the Assessment of Histological Healing. Biomedicines 2023; 11(11) doi: 10.3390/biomedicines11113090
9	Reem Al-jabri, Panu Wetwittayakhlang, Peter L. Lakatos. Monitoring of Inflammatory Bowel Disease in Pregnancy: A Review of the Different Modalities. Journal of Clinical Medicine 2023; 12(23) doi: 10.3390/jcm12237343
10	Livia Lontai, Lorant Gonczi, Fruzsina Balogh, Nora Komlodi, Tamas Resal, Klaudia Farkas, Tamas Molnar, Pal Miheller, Petra A. Golovics, Eszter Schafer, Tamas Szamosi, Akos Ilias, Peter L. Lakatos. Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease – a prospective, multicentre study. Digestive and Liver Disease 2022; 54(12) doi: 10.1016/j.dld.2022.07.004
11	Mahmoud E. Kamal, Rehab H. Werida, Mahasen A. Radwan, Safaa R. Askar, Gamal A. Omran, Marwa A. El-Mohamdy, Radwa S. Hagag. Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients. Inflammopharmacology 2024; 32(5) doi: 10.1007/s10787-024-01508-w
12	Lynna Chen, Ashish Srinivasan, Suet‐Wan Choy, Jeffrey Van, Habeeb Habeeb, Andrew Nguyen, Abhinav Vasudevan. Prescribing Inflammatory Bowel Disease Medications in Chronic Kidney Disease: A Practical Guide. Alimentary Pharmacology & Therapeutics 2025; 62(4) doi: 10.1111/apt.70262
13	Wen-Hang Xu, Yi-Hong Fan. Progress in understanding of relationship between blood concentrations of ustekinumab and clinical outcomes of inflammatory bowel disease. World Chinese Journal of Digestology 2025; 33(4) doi: 10.11569/wcjd.v33.i4.261 Abstract(0) \| Core Tip(0) \| Full Article(HTML)(0) \| Times Cited (0) \| Total Visits (0) \| Open
14	Brindusa Truta. Therapeutic drug monitoring in inflammatory bowel disease: At the right time in the right place. World Journal of Gastroenterology 2022; 28(13): 1380-1383 doi: 10.3748/wjg.v28.i13.1380 Abstract(1124) \| Core Tip(1281) \| Full Article(HTML)(3623) \| Full Article (PDF)-578K(538) \| Full Article (Word)-113K(155) \| Audio-454K(14) \| Peer-Review Report-246K(224) \| Answering Reviewers-59K(218) \| Times Cited (1) \| Total Visits (4316) \| Open
15	Queeneth Edwards, Oluwatoyin Ayo-Farai, Fidelis E Uwumiro, Babajide Komolafe, Odigili E Chibuzor, Ifeanyi Agu, Henry O Nwuke, Gentle C Uwaoma, Emmanuel S Amadi, Marvis Enyi, Courage Idahor, Chinyere K Omeh. Decade-Long Trends in Hospitalization, Outcomes, and Emergency Department Visits for Inflammatory Bowel Diseases in the United States, 2010 to 2020. Cureus 2025; doi: 10.7759/cureus.77941
16	Hussein Hazim Saleh, Dheyaa Jabbar Khadim , Raghad Jawad Hussein. Correlation between Therapeutic Drug Monitoring of Infliximab Serum Trough Levels and other Biomarkers in Iraqi Patients with Crohn's Disease. Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 ) 2024; 6(1) doi: 10.54133/ajms.v6i1.606
17	Joseph William Clinton, Raymond Keith Cross. Personalized Treatment for Crohn’s Disease: Current Approaches and Future Directions. Clinical and Experimental Gastroenterology 2023; doi: 10.2147/CEG.S360248
18	Matthew B. Stanton, Mark A. Solinski, Stephen B. Hanauer. Genetic polymorphisms impacting clinical pharmacology of drugs used to treat inflammatory bowel disease: a precursor to multi-omics approach to precision medicine. Expert Review of Clinical Immunology 2025; 21(4) doi: 10.1080/1744666X.2025.2461584
19	Rachel Levy, Manar Matar, Maya Zvuloni, Raanan Shamir, Amit Assa. Trough Concentration Response in Infliximab and Adalimumab Treated Children With Inflammatory Bowel Disease Following Treatment Adjustment. Journal of Pediatric Gastroenterology and Nutrition 2023; 76(5) doi: 10.1097/MPG.0000000000003726
20	Krishneel Dutt, Abhinav Vasudevan. Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease. Medicina 2024; 60(2) doi: 10.3390/medicina60020250
21	Niloofar Khoshnam Rad, Ghazal Roostaei, Shekoufeh Nikfar, Mohammad Abdollahi. Transforming IBD care: the future of personalized therapy through multi-omics and pharmacogenomics. Expert Opinion on Drug Metabolism & Toxicology 2025; 21(8) doi: 10.1080/17425255.2025.2521048
22	Rachel C. Cogan, Basem W. El-Matary, Wael M. El-Matary. Therapeutic drug monitoring for biological medications in inflammatory bowel disease. Saudi Journal of Gastroenterology 2022; 28(5) doi: 10.4103/sjg.sjg_3_22
23	Vlasta Oršić Frič, Vladimir Borzan, Ines Šahinović, Andrej Borzan, Sven Kurbel. Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience. Pharmaceuticals 2023; 16(2) doi: 10.3390/ph16020239